Document is current

Article History

Received: 30 December 2022

Accepted: 13 April 2023

First Online: 16 May 2023

Declarations

:

: The study was approved by the institutional review boards or independent ethics committees at each participating center. Written informed consent was obtained from all enrolled patients.

: Not applicable.

: JB: Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly consultant for: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly and received speakers bureau fees from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB pharma, Eli Lilly.RB: Research grants - AbbVie, MSD, and Roche; consulting fees - AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD; Speaker's bureau - AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD and Lilly.HMO: research funds from Janssen, Novartis, UCB and consulting and speaking fees from AbbVie, Celgene, Janssen, Eli Lilly and Company, MoonLake, Novartis, Pfizer, Takeda, and UCB. Supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC).LSG: grant/research support from UCB, and consulting fees from AbbVie, Acelyrin, Gilead, Eli Lilly, Fresenius Kabi, Janssen, MoonLake, Novartis, Pfizer and UCB.FVB: reports research grants, consultancy fees or speaker honoraria from AbbVie, BMS, Amgen, Galapagos, Janssen, Eli Lilly, Merck, MoonLake, Novartis, Pfizer and UCB.SH: consulting fees, speaking fees, and/or honoraria from Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCB and research support from AbbVie, UCB, Janssen, and Merck.HK: Grant/research support from: Abbvie, Asahi-Kasei, Boehringer, Chugai, Eisai, Mitsubishi-Tanabe and Taisho, consultant for: Abbvie, Astellas, Boehringer, Eli Lilly, Gilead Sciences, Janssen, Medac, Novartis, Sanofi, Taisho, UCB, and received speaker bureau fees from: Abbvie, Asahi-Kasei, Astellas, BMS, Chugai, Eisai, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe, Novartis and Pfizer.DP: Research grant from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, Consultation fees from AbbVie, Biocad, BMS, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Samsung Bioepis, UCB, Speaker fees from, AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, UCB.MVS: Grant/research support from: Novartis, Eli Lilly, Janssen, UCB Consultant fee: Abbvie, Novartis, Eli Lily, UCB; Speaker fee: Novartis, UCB, Janssen.DVH: Personal fees from Novartis, AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Pfizer, UCB Pharma, and Director of Imaging Rheumatology bv.TZ: Employee of Novartis and owns Novartis stock.AS: Employee of Novartis and owns Novartis stock.AR: Employee of Novartis and owns Novartis stock.HBR: Employee of Novartis and owns Novartis stock.AD: Grant/research support from: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant for AbbVie, Amgen, Aurinia, Bristol-Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, Moonlake, Novartis, Pfizer, and UCB, speaking for AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.